Once-daily antiretroviral therapies for HIV infection: Consensus statement of an advisory committee of the international association of physicians in AIDS care

Journal of the International Association of Physicians in AIDS Care

Volumn 1, Issue 4, 2002, Pages 141-145

  Cohen, Calvin ^a   Elion, Richard A ^b   Frank, Ian ^c   Kloser, Patricia ^d   Sherer, Renslow ^e   Squires, Kathleen E ^f   Steinhart, Corklin ^g   Tebas, Pablo ^h  

^a Boston Community Research Initiative of New England   (United States)

^b AIDS Clinical Trials Unit ^*  (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^e The CORE Center   (United States)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g Washington University School of Medicine   (United States)

^h WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

antiretroviral; once daily dosing; pharmacokinetics; twice daily dosing

Indexed keywords

ANTIRETROVIRUS AGENT;

CONFERENCE PAPER; CONSENSUS DEVELOPMENT; DRUG ADMINISTRATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PATIENT COMPLIANCE; VIRUS LOAD;

ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG ADMINISTRATION SCHEDULE; HIV INFECTIONS; HUMANS; PATIENT COMPLIANCE; VIRAL LOAD;

EID: 1542646440     PISSN: 15451097     EISSN: 15570886     Source Type: Journal    
DOI: 10.1177/154510970200100406     Document Type: Article

References (32)

1. Moyle G. The once-a-day era is upon us. AIDS Reader 2002 ; 12 (2). 56-58. (Pubitemid 34202702)
2. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000 ; 133 (1). 21-30. (Pubitemid 30432540)
3. US DHHS Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. February 4, 2002. Online at www.hivatis.org
4. AWARE Treatment Lifestyle Survey, December 2001.
5. Bristol-Myers Squibb Virology Survey of POZ Magazine Readers. POZ Magazine, December 2001.
6. Jordan J, Carranza Rosenweig J, Pathak D, et al. Perceived influence of regimen characteristics on adherence. 5th International Congress on Drug Therapy in HIV Infection. Glasgow, Scotland. October 22-26, 2000. (Abstract P121).
7. Badaro R, Gathe J, Grimwood A, et al. Evaluation of a triple combination regimen containing enteric-coated didanosine administered once daily. 1st IAS Conference on HIV Pathogenesis and Treatment. Buenos Aires, Argentina. July 8-11, 2001. (Abstract 57).
8. Roca B, et al. Adherence and efficacy of HAART with bid or qd didanosine. 14th International AIDS Conference. Barcelona, Spain. July 7-12, 2002. (Abstract WePeB5815).
9. Sension M, Bellos N, Johnson J, et al. Efficacy and safety of switch to 3TC 300 mg QD vs. Continued 3TC 150 mg BID in subjects with virologic suppression on stable 3TC/d4T/PI therapy (COLA 4005): Final 24-week results. 8th Conference on Retroviruses and Opportunistic Infections. Chicago, IL. February 4-8, 2001. (Abstract 317).
10. Bruno R, Ciappina V, Villani P, et al. Comparison of the plasma pharmacokinetics of lamivudine during twice and once daily dosing in HIV-1 infected individuals. 1st IAS Conference on HIV Pathogenesis and Treatment. Buenos Aires, Argentina. July 8-11, 2001. (Abstract 342).
11. Schooley R, Myers R, Ruane P, et al. Tenofovir disoproxil fumarate (TDF) for the treatment of antiretroviral-experienced patients: A double blind placebo-controlled study. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada. September 17-20, 2000. (Abstract 692).
12. Louie M, Hogan C, Hurley A, et al. Determining the relative efficacy of Tenofovir DF using frequent measurements of HIV-1 RNA during a short course of monotherapy in antiretroviral drug naïve individuals. 9th Conference on Retroviruses and Opportunistic Infections. Seattle, WA. February 24-28, 2002. (Abstract 3).
13. Pollard RB, et al. Stavudine extended/prolonged release (XR/PRC) vs stavudine immediate release (IR) in combination with lamivudine and efavirenz: 48 week efficacy and safety. 14th International AIDS Conference. Barcelona, Spain. July 7-12, 2002. (Abstract LbPeB9014).
14. Arribas J, Staszewski M, Nelson M. Three-year durability of response with an efavirenz (EFV)-containing regimen: 144-week follow-up of study 006. 11th European Congress of Clinical Microbiology and Infectious Diseases. Istanbul, Turkey. April 1-4, 2001.
15. Raffi F, Reliquet V, Ferre V, et al. d4T + qd ddI + nevirapine (bid or qd) in antiretroviral-naïve HIV-1-infected patients: 1-year results of the VIRGO study. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA. September 26-29, 1999. (Abstract 1978).
16. Murphy RL, Katlama C, Johnson V, et al. The Atlantic Study: A randomized, open-label trial comparing two protease inhibitor (PI)-sparing antiretroviral strategies versus a standard PI-containing regimen, 48-week data. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA. September 26-29, 1999. (Abstract LB-22).
17. Felipe G, Hernando K, Antonia SM, et al. An open randomized study comparing d4T + ddI + nevirapine (QD) vs d4T + ddI + nevirapine (BID) in antiretroviral-naïve, chronic HIV-infected patients in very early stage: Spanish scan study - Final results. XIII International AIDS Conference. Durban, South Africa. July 9-14, 2000. (Abstract 1156).
18. Sanne I, Cahn P, Percival L, et al. Comparative results (phase II, 48-week): BMS232632, stavudine, lamivudine as HAART for treatment-naïve HIV(+) patients (A1424-008). 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL. December 16-19, 2001. (Abstract 1-667).
19. Maggiolo F, Migliorino M, Maserati R, et al. Once-a-day treatment for HIV infection: Final 48-week results. 8th Conference on Retroviruses and Opportunistic Infections. Chicago, IL. February 4-8, 2001. (Abstract 320).
20. Landman R, Thiam S, et al. Long-term evaluation (15 months) of ddI, 3TC and efavirenz once-daily regimen in naïve patients in Senegal: ANRS 12-04 study/IMEA 011 study. 9th Conference on Retroviruses and Opportunistic Infections. Seattle, WA. February 24-28, 2002. (Abstract 458-W).
21. Molina JM, Perusat S. Ferchal F, et al. Once-daily combination therapy with emtricitabine, didanosine and efavirenz in treatment naïve HIV-infected adults: 64-week follow-up of the ANRS 091 trial. 8th Conference on Retroviruses and Opportunistic Infections. Chicago, IL. February 4-8, 2001. (Abstract 321).
22. Sustiva, full prescribing information, Bristol-Myers Squibb Company, 2002.
23. Videx EC, full prescribing information, Bristol-Myers Squibb Company, 2001.
24. Viread, full prescribing information, Gilead Sciences Inc., 2001.
25. Epivir, full prescribing information, GlaxoSmithKline, 2001.
26. Norvir, full prescribing information, Abbott Laboratories, 2001.
27. Rosenbach KA, Allison R, Nadler JP. Daily dosing of highly active antiretroviral therapy. Clin Infect Dis 2002 ; 34 (5). 686-692. (Pubitemid 34165333)
28. Suleiman J, Rhodes R, Campo R, et al. Preliminary results from indinavir (IDV), and ritonavir (RTV) in a once daily regimen (Merck 103/104). 8th Conference on Retroviruses and Oportunistic Infections. Chicago, IL. February 4-8, 2001. (Abstract 336).
29. Saah A, Winchell G, Seniuk M, et al. Multiple-dose pharmacokinetics (PK) and tolerability of indinavir (IDV) and ritonavir (RTV) combinations in a once-daily regimen in healthy volunteers (Merck 089). 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA. September 26-29, 1999. (Abstract 329).
30. Hsyu PH, Lewis R, Tran J, et al. Pharmacokinetics (PK) of nelfinavir (NFV) after once-daily dosing in combination with mini-doses of ritonavir (RTV) in healthy subjects. XIII International AIDS Conference. Durban, South Africa. July 9-14, 2000. (Abstract 7049).
31. Becker S, Hodder S, Burtcel B, et al. Antiretroviral therapy adherence as measured by prescription refill behavior: A large claims database study. 8th European Conference on Clinical Aspects and Treatment of HIV Infection. Athens, Greece. October 28-31, 2001. (Abstract 80).
32. Fischl M, Castro J, Monroig R, et al. Impact of DOT on long-term outcomes in HIV clinical trials. 8th Conference on Retroviruses and Opportunistic Infections. Chicago, IL. February 4-8, 2001. (Abstract 528).